Get started
Author

Lucrezia Principi

ORCID: 0000-0002-0391-7995
Observed ORCID: 0000-0002-0391-7995
OpenAlex ID: A5007705010
Spatial Multiomics of Lipids, N-Glycans, and Tryptic Peptides on a Single FFPE Tissue Section
2022 · Vanna Denti, Giulia Capitoli, et al. · Journal of Proteome Research · 45
A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule–Drug, Antibody–Drug, and Peptide–Drug Conjugates
2023 · Aureliano Zana, Claudia Puig-Moreno, et al. · Bioconjugate Chemistry · 35
In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment
2024 · Matilde Bocci, Aureliano Zana, et al. · Journal of Controlled Release · 34
Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy
2025 · Tony Georgiev, Francesca Migliorini, et al. · Nature Biomedical Engineering · 30
Proteomic Fingerprint of Lung Fibrosis Progression and Response to Therapy in Bleomycin-Induced Mouse Model
2023 · Lucrezia Principi, Erica Ferrini, et al. · International Journal of Molecular Sciences · 18
PDF
PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer
2025 · Tony Georgiev, Sara Puglioli, et al. · Molecular Cancer Therapeutics · 9
Spatially Resolved Molecular Approaches for the Characterisation of Non-Invasive Follicular Tumours with Papillary-like Features (NIFTPs)
2023 · Isabella Piga, Vincenzo L’Imperio, et al. · International Journal of Molecular Sciences · 9
PDF
Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™
2024 · Tony Georgiev, Lucrezia Principi, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 7
Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker
2023 · Lydia Bisbal Lopez, Domenico Ravazza, et al. · Frontiers in Pharmacology · 7
Delivery of Monomethyl Auristatin F to the Tumor Microenvironment with Noninternalizing Fibroblast Activation Protein-Cleavable Small Molecule–Drug Conjugates Elicits Potent In Vivo Anticancer Activity
2024 · Matilde Bocci, Lucrezia Principi, et al. · Bioconjugate Chemistry · 6
Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics
2025 · Matilde Bocci, Lucrezia Principi, et al. · Molecular Cancer Therapeutics · 5
Correction to Spatial Multiomics of Lipids, N-Glycans, and Tryptic Peptides on a Single FFPE Tissue Section
2023 · Vanna Denti, Giulia Capitoli, et al. · Journal of Proteome Research · 4
PDF
Combination with Immunocytokines Enhances the Anticancer Activity of Small Molecule Drug Conjugates and Radioligand Therapeutics Targeting Fibroblast Activation Protein
2026 · Matilde Bocci, Laura Lucaroni, et al. · Molecular Pharmaceutics · 3
Figure S4 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics
2025 · Matilde Bocci, Lucrezia Principi, et al.
Figure S2 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics
2025 · Matilde Bocci, Lucrezia Principi, et al.
Supplementary Information from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics
2025 · Matilde Bocci, Lucrezia Principi, et al.
Figure S5 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics
2025 · Matilde Bocci, Lucrezia Principi, et al.
Figure S1 from Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics
2025 · Matilde Bocci, Lucrezia Principi, et al.
Supplementary Figure S4 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer
2025 · Tony Georgiev, Sara Puglioli, et al.
Supplementary Figure S5 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer
2025 · Tony Georgiev, Sara Puglioli, et al.
Supplementary Figure S11 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer
2025 · Tony Georgiev, Sara Puglioli, et al.
Supplementary Table S1 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer
2025 · Tony Georgiev, Sara Puglioli, et al.
Supplementary Figure S14 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer
2025 · Tony Georgiev, Sara Puglioli, et al.
Supplementary Figure S8 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer
2025 · Tony Georgiev, Sara Puglioli, et al.
Supplementary Information (SI) from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer
2025 · Tony Georgiev, Sara Puglioli, et al.
Works count: 44
Citation count: 212
H-index: 7
I10-index: 5
Year
Topic
Type